Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $37.54 in the prior trading day, Xenon Pharmaceuticals Inc (NASDAQ: XENE) closed at $35.18, down -6.29%. In other words, the price has decreased by -$6.29 from its previous closing price. On the day, 1.35 million shares were traded.
Ratios:
Our goal is to gain a better understanding of XENE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.85 and its Current Ratio is at 17.85. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Buy rating and assigned the stock a target price of $67.
On October 01, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $53.H.C. Wainwright initiated its Buy rating on October 01, 2024, with a $53 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 24 ’25 when MORTIMER IAN sold 22,468 shares for $40.20 per share. The transaction valued at 903,214 led to the insider holds 31,302 shares of the business.
MORTIMER IAN sold 16,315 shares of XENE for $660,806 on Jan 27 ’25. The PRESIDENT & CEO now owns 31,302 shares after completing the transaction at $40.50 per share. On Jan 23 ’25, another insider, MORTIMER IAN, who serves as the PRESIDENT & CEO of the company, sold 16,217 shares for $40.08 each. As a result, the insider received 649,977 and left with 31,302 shares of the company.
Stock Price History:
Over the past 52 weeks, XENE has reached a high of $46.00, while it has fallen to a 52-week low of $26.74. The 50-Day Moving Average of the stock is 0.36%, while the 200-Day Moving Average is calculated to be -10.34%.
Shares Statistics:
A total of 76.42M shares are outstanding, with a floating share count of 74.25M. Insiders hold about 3.05% of the company’s shares, while institutions hold 97.27% stake in the company.
Earnings Estimates
The current rating of Xenon Pharmaceuticals Inc (XENE) reflects the combined expertise of 12.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.98, with high estimates of -$0.79 and low estimates of -$1.14.
Analysts are recommending an EPS of between -$3.2 and -$4.67 for the fiscal current year, implying an average EPS of -$4.05. EPS for the following year is -$4.55, with 11.0 analysts recommending between -$3.67 and -$5.31.
